BioCentury
ARTICLE | Product Development

Oxford adds to surge of pandemic deals, enlisting more manufacturers for COVID-19 vaccine

BioCentury is providing this story for free given the urgent need for information about the COVID-19 crisis. For more analysis, sign up for our daily email.

April 17, 2020 1:07 PM UTC

With the Phase I trial of its COVID-19 vaccine enrolling patients, the University of Oxford has added two more manufacturing partners -- Merck KGaA and Halix B.V. -- to its consortia.

The move follows that of several large pharmas and biotechs that have secured manufacturing capacity before, or in parallel with, clinical testing of COVID-19 vaccines and therapeutics in hopes of creating a quick and seamless path to market (see “Dealmaking in a Pandemic”). ...



Access The Full Article

BCIQ Company Profiles

University of Oxford

Merck KGaA